Domov › Rakovina vaječníkov › Texas › Dallas
Klinické štúdie Rakovina vaječníkov v meste Dallas, TX
28 štúdií pre Rakovina vaječníkov hľadá účastníkov v zariadeniach v meste Dallas a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Prebieha náborFáza 2/3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Prebieha náborFáza 2
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Prebieha náborFáza 1/2
- UT Southwest Simmons Cancer Center, Dallas
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Prebieha náborFáza 1
- UT Southwestern, Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Avenzo Therapeutics Recruiting Site, Dallas
DESTINY-PANTUMOUR04
Prebieha náborObservačná štúdia
- Research Site, Dallas
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Prebieha náborFáza 3
- UT Southwestern Medical Center, Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Prebieha náborFáza 1
- Texas Oncology - DFW (Sammons CC), Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Prebieha náborObservačná štúdia
- UT Southwestern Medical Center, Dallas
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Prebieha náborFáza 2
- UT Southwestern Medical Center, Dallas
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Prebieha náborFáza 1
- SCRI - Mary Crowley Cancer Research, Dallas
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Prebieha náborFáza 1
- Normunity Investigational Site, Dallas
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Prebieha náborFáza 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Prebieha náborFáza 1/2
- Texas Oncology, P.A., Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Prebieha náborFáza 1/2
- Mary Crowley Cancer Research, Dallas
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Mary Crowley Cancer Research, Dallas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Prebieha náborFáza 2
- Baylor Scott & White Research Institute, Dallas
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Prebieha náborFáza 2
- Texas Oncology - DFW, Dallas
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- University of Texas Southwestern, Dallas
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Prebieha náborFáza 1/2
- Texas Oncology, P.A., Dallas
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
Prebieha nábor
- UT Southwestern Parkland Health and Hospital System, Dallas
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Prebieha náborFáza 1/2
- Next Oncology, Dallas
- UTSW Medical Center, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Prebieha náborFáza 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Prebieha náborFáza 1
- Dren Investigational Site, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, Dallas
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Prebieha náborFáza 1/2
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Prebieha náborFáza 1
- Mary Crowley Cancer Research, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Prebieha náborFáza 1
- NEXT Oncology, Dallas, Dallas
Štúdie Rakovina vaječníkov v iných mestách
- Houston, TX89 štúdií
- New York City, NY69 štúdií
- Boston, MA61 štúdií
- Los Angeles, CA50 štúdií
- Nashville, TN49 štúdií
- Arlington, VA46 štúdií
- Philadelphia, PA44 štúdií
- Columbus, OH39 štúdií
- St. Louis, MO38 štúdií
- Chicago, IL36 štúdií
- San Antonio, TX31 štúdií
- Cleveland, OH30 štúdií
Iné štúdie v Dallas
- Rakovina prsníka55 štúdií
- Nemalobunkový karcinóm pľúc52 štúdií
- Metastatická rakovina42 štúdií
- Srdcové zlyhanie42 štúdií
- Rakovina (všetky typy)37 štúdií
- Rakovina prostaty36 štúdií
- Kolorektálny karcinóm33 štúdií
- Obézita30 štúdií
- Rakovina pľúc27 štúdií
- Rakovina močového mechúra27 štúdií
- Rakovina endometria24 štúdií
- Rakovina obličiek (renálny bunkový karcinóm)23 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.